Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multi-center open-label uncontrolled study in patients with ventricular arrhythmia

Next Previous
X
Search
Trial Profile

A multi-center open-label uncontrolled study in patients with ventricular arrhythmia

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 07 Dec 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Landiolol (Primary)
  • Indications Ventricular arrhythmias
  • Focus Registrational; Therapeutic Use
  • Sponsors Ono Pharmaceutical

    • Most Recent Events

    • 23 May 2019 Primary endpoint of proportion of patients free from recurrent hemodynamically unstable VT or the proportion of patients free from recurrent VF has been met according to results published in the Circulation Journal.
    • 23 May 2019 Results published in the Circulation Journal
    • 26 Mar 2019 According to an Ono Pharmaceutical media release, based on the results of this study, the company received an approval for ONOACT (landiolol hydrochloride) for intravenous infusion (50mg/150mg) for indication of ventricular arrhythmia as a partial change in the approved items of the manufacturing and marketing approval in Japan.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top